EUCTR2005-005913-40-IT进行中（未招募）不适用
A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassemia Major - ND
OSPEDALE POLICLINICO S. MATTEO0 个研究点目标入组 10 人开始时间: 2006年3月15日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- patients affected by Thalassemia Major - age 1-30 years old, etc...
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- not provided written voluntary informed consent by parents -hepatic desease, etc...
研究者
相似试验
招募中
1 期
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaHepatocellular carcinomaCTIS2023-505698-34-00Merck Sharp & Dohme LLC102
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinoma without any prior systemic treatmentMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004490-52-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.110
进行中（未招募）
2 期
Phase 2 Study of MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaAdvanced hepatocellular carcinomaJPRN-jRCT2061210033Hoki Toshifumi6
进行中（未招募）
1 期
Phase 2 Study of MK 1308A (Coformulated MK 1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular CarcinomaEUCTR2020-004490-52-PLMerck Sharp & Dohme LLC110
进行中（未招募）
1 期
A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery - RADHEREUCTR2007-004098-24-FRFNCLCC82